Compare · ILMN vs MSON
ILMN vs MSON
Side-by-side comparison of Illumina Inc. (ILMN) and MISONIX, Inc. (MSON): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while MSON operates in Capital Goods - the two are in different parts of the market.
- ILMN is the larger of the two at $24.56B, about 53.1x MSON ($462.5M).
- ILMN has hit the wire 22 times in the past 4 weeks while MSON has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 2 for MSON).
- Company
- Illumina Inc.
- MISONIX, Inc.
- Price
- $158.97-2.04%
- $26.23+3.72%
- Market cap
- $24.56B
- $462.5M
- 1M return
- +14.62%
- -
- 1Y return
- +87.07%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 1992
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 2
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
MISONIX, Inc.
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest MSON
- SEC Form 4: Koby Michael returned 1,744,017 shares to the company
- SEC Form 4: Vizirgianakis Stavros G. returned 2,136,478 shares to the company, closing all direct ownership in the company
- SEC Form 4: Patton Thomas M returned 104,500 shares to the company, closing all direct ownership in the company
- SEC Form 4: Ludecker Robert S returned 319,443 shares to the company, closing all direct ownership in the company
- SEC Form 4: Laviolette Paul A returned 1,744,017 shares to the company
- SEC Form 4: Dwyer Joseph P returned 276,200 shares to the company, closing all direct ownership in the company
- SEC Form 4: Beyer Pat returned 20,000 shares to the company, closing all direct ownership in the company
- SEC Form RW filed by MISONIX, Inc.
- SEC Form 15-12B filed by MISONIX, Inc.
- MISONIX, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits